Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
infection (rCDI) often occurs after successful treatment of CDI. Due to the increased incidence and the difficulty in treating rCDI, it is becoming an important clinical issue. Identifying risk factors is helpful for early detection, treatment, and prevention of rCDI. Advanced age, use of antibiotics, gastric acid suppression, and infection with a hypervirulent strain are currently regarded as the major risk factors for rCDI. Several treatment modalities, including vancomycin, fidaxomicin, and fecal microbiota transplant (FMT), are suggested for rCDI treatment. However, there is currently no definitive treatment method with sufficient evidence for rCDI. Recent studies have focused on FMT and have shown positive results for rCDI. Prevention of rCDI by measures such as hand washing and isolation of patients is very important. However, these preventive measures are often overlooked in clinical practice. Here, we review the risk factors, treatment, and prevention of rCDI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“In an openlabel randomized controlled clinical trial, 43 patients with rCDI received one of three treatments: (1) a vancomycin regimen followed by bowel lavage and subsequent FMT through a nasoduodenal tube; (2) a vancomycin regimen alone; or (3) a vancomycin regimen with bowel lavage.(57) The cure rate for the FMT gr…”
MethodDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“However, antibiotics reduce the diversity of the intestinal microbiota.(46) Compared with the fecal microbiota of patients without CDI, the fecal microbiota of patients with rCDI is more variable in bacterial composition and is characterized by a marked decrease in ecological diversity and lower species richness.”
BackgroundGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 1×
“boulardii alone had a significant decrease in rCDI.(74) However, a Cochrane review concluded that probiotics as an adjunct to antibiotic therapy did not have sufficient evidence and probiotics alone had no evidence for the treatment of CDI.”
BackgroundBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 1×
“FMT restores these changes in bacterial composition and improves rCDI symptoms.(48) Studies have shown that FMT produced a primary cure rate of approximately 90% in patients with rCDI.”
BackgroundQuraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
Mizuno, S., Masaoka, T., Naganuma, M., Kishimoto, T., Kitazawa, M., Kurokawa, S., Nakashima, M., Takeshita, K., Suda, W., Mimura, M., et al. (2017) · Digestion · doi:10.1159/000471919 · Cited by 395
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371
Abou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098400 · Cited by 328
Fecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231 · cited 1×
“Another potential problem of FMT is that changes in gut microbiota can affect various extraintestinal disorders, such as metabolic, neuropsychiatric, autoimmune, and tumorous disorders.(68)”
BackgroundRifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
Koo, H. L., & DuPont, H. L. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328333dc8d · Cited by 189 · cited 2×
“difficile, rifaximin produces minimal alterations in the intestinal microflora.(69) This is the basis for considering rifaximin as a treatment option for rCDI.”
Background
Cited by
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Postbiotics as potential new therapeutic agents for sepsis
Lou, X., Xue, J., Shao, R., Mo, C., Wang, F., & Chen, G. (2023) · Burns & Trauma · doi:10.1093/burnst/tkad022 · Cited by 38
Contribution of gut microbiota toward renal function in sepsis
Xu, Y., Kong, X., Zhu, Y., Xu, J., Mao, H., Li, J., Zhang, J., & Zhu, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.985283 · Cited by 22
“Many broad-spectrum antibiotics inhibit or kill dominant flora, leading to increased colonization of conditioned pathogenic bacteria and fungi, and ultimately resulting in opportunistic or secondary infections and exacerbation of intestinal microbiome imbalances (Song and Kim, 2019).”
Background
Metadata
- Authors
- Song, J. H., & Kim, Y. S.
- Venue
- Gut and Liver
- Published
- 2019-01-15
- Volume
- 13
- Issue
- 1
- Pages
- 16-24
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W2900381242
- Cited by
- 219
- References
- 13
- FWCI
- 5.36
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.